Investing.comDoubao · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 20:12:29·⟳ 抓取 20:12:54 +25s·⚡ 决策 10-19 20:19:22 +6m28s·8.3 天前
TransCode（RNAZ）公告 TTX-MC138 的 1a 期数据摘要获 ESMO 2026 接收为壁报，无新数据
这是一条学术会议壁报接收的预告性新闻稿，展示内容是已在 AACR 2025/2026 公开过的 1a 期数据，没有新的疗效/安全性读数或财务增量；RNAZ 为约 2,900 万美元市值的纳米盘，日均成交约 9.7 万美元、盘后买卖价差约 12%，13 周股价单边下行（距 52 周高点 -89%），既无基本面催化也无可执行流动性，不构成多空任一方向的正期望。
📄 原文Investing.com↗ 原文
TransCode to present phase 1a data at ESMO congress
BOSTON - TransCode Therapeutics Inc. (NASDAQ:RNAZ) announced a poster presentation featuring its lead therapeutic candi…
不做 TransCode Therapeutics（RNAZ.US）
无新增事实：ESMO 壁报仅复述 AACR 2025/2026 已公开的 1a 期数据，本次为预告性公关稿；且 RNAZ 为约 2,900 万美元纳米盘，日均成交约 9.7 万美元、盘后价差约 12%、13 周走势持续下行（距 52 周高点 -89%），多空均无正期望与可执行性。真正的潜在波动点在壁报当日（10月23-27日期间），若届时有新数据应作为独立事件重判。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
RNAZ 仅宣布 ESMO 壁报获接收、将复述已在 AACR 公开的 1a 期数据，无新增临床事实；叠加纳米盘极低流动性和下行趋势，消息级与可交易性均不足，回避。
🔎 新鲜度:最早出现 2026-10-19 · 扩散 low · price-in 风险 low ↗
消息传播链
- RNAZ 公告 TTX-MC138 的 1a 期壁报获 ESMO 2026 接收，将于大会周四展示；为预告性新闻稿，无新数据；未定位到公司 IR 原稿链接，以转述为准
关键理由
- 本次发布不含任何新数据，仅是 10 月下旬 ESMO 壁报的接收预告，1a 期数据此前已两次在 AACR 公开
主要风险
- 纳米盘生物股会议前可能出现情绪性脉冲（pump），但日均成交不足 10 万美元、价差约 12%，追高与退出均极易受损；若壁报意外公布超预期新数据才可能改变判断
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-19 · 影响 invalidates
未发现本次将公布新疗效读数的证据；内容为已公开 1a 期数据的会场复述，且 ADV 仅约 9.7 万美元、价差约 12%、13 周单边下跌，做多不成立
检索:TransCode TTX-MC138 ESMO 2026 new data readout efficacy 原文 ↗ - 做空前查反向 · 来源 web · 影响 none
虽为持续烧钱的临床期纳米盘（PE 为负、S-3 在册提示融资摊薄可能），但本事件本身非利空、无强空催化，不符合做空红线
检索:TransCode Therapeutics funding cash runway dilution 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:支持当前不交易；如壁报当日出现真实新数据，应作为独立新事件重新研判
方向:未做先例统计：本次结论基于无增量事实与流动性不足即 AVOID，先例涨幅不会改变回避结论
涨幅量级:不适用（无 ENTER 腿，无需校准幅度）
形态:纳米盘临床期生物股的会议壁报接收预告通常为非催化型公关稿；1a 期数据已在 AACR 两次公开，真正的波动窗口（若有）在壁报当日而非现在
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`transcode therapeutics esmo congress accepted poster | transcode therapeutics rnaz ttx-mc138 esmo 2026 poster presentation | ttx-mc138 phase 1a antagomir mir-10b esmo madrid`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query - stock_quote 成功 stock_tools HTTP · 1,319 ms
{ - web_search 成功 doubao_search · 1,943 ms
豆包搜索结果（原始查询:TransCode Therapeutics TTX-MC138 phase 1a data presented AACR 2025 results；API SearchType:web）
原文全文
展开原文 · 1,510 字
BOSTON - TransCode Therapeutics Inc. (NASDAQ:RNAZ) announced a poster presentation featuring its lead therapeutic candidate TTX-MC138 has been accepted for the European Society for Medical Oncology Congress 2026 in Madrid, Spain, according to a press release statement.
The poster, titled "Phase 1a Clinical Trial of TTX-MC138, a First-in-Class AntagomiR against Advanced Solid Tumors," will be presented on Thursday at the congress. The presentation will highlight clinical data from the Phase 1a evaluation of TTX-MC138 in patients with advanced solid tumors.
TTX-MC138 is an investigational therapeutic designed to target miR-10b, a microRNA associated with metastatic disease progression. The company describes the drug as targeting a biomarker of metastasis.
"We are honored to have the opportunity to present our most recent TTX-MC138 clinical results at ESMO, one of the world’s leading oncology meetings," said Zdravka Medarova, Chief Scientific Officer of TransCode.
The ESMO Congress 2026 runs from October 23 through October 27, 2026 in Madrid.
TransCode is a clinical stage company focused on immuno-oncology and RNA-based therapeutics for treating high risk and advanced cancers. The company is currently evaluating TTX-MC138 in a Phase 2a trial under the PRE-I-SPY program in collaboration with Quantum Leap Healthcare Collaborative.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
TransCode to present phase 1a data at ESMO congress
The poster, titled "Phase 1a Clinical Trial of TTX-MC138, a First-in-Class AntagomiR against Advanced Solid Tumors," will be presented on Thursday at the congress. The presentation will highlight clinical data from the Phase 1a evaluation of TTX-MC138 in patients with advanced solid tumors.
TTX-MC138 is an investigational therapeutic designed to target miR-10b, a microRNA associated with metastatic disease progression. The company describes the drug as targeting a biomarker of metastasis.
"We are honored to have the opportunity to present our most recent TTX-MC138 clinical results at ESMO, one of the world’s leading oncology meetings," said Zdravka Medarova, Chief Scientific Officer of TransCode.
The ESMO Congress 2026 runs from October 23 through October 27, 2026 in Madrid.
TransCode is a clinical stage company focused on immuno-oncology and RNA-based therapeutics for treating high risk and advanced cancers. The company is currently evaluating TTX-MC138 in a Phase 2a trial under the PRE-I-SPY program in collaboration with Quantum Leap Healthcare Collaborative.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
TransCode to present phase 1a data at ESMO congress
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
ef151d46f4· 2026-10-19 20:19 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前